Vimarsana
Biggest News Aggregation in the World

Page 4 - Therapeutic Vector Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Therapeutic Vector Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Therapeutic Vector Evolution Today - Breaking & Trending Today

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - 4D Molecular Therapeutics (NASDAQ:FDMT), Astellas Pharma (OTC:ALPMY) - Vimarsana News

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - 4D Molecular Therapeutics (NASDAQ:FDMT), Astellas Pharma (OTC:ALPMY)

Published: July 11, 2023

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) (CEO: David Kirn, MD,

Source: benzinga.com
Related Topics:
David KirnNaoki OkamuraAdam PearsonAstellas Pharma IncPrnewswire Astellas Pharma IncD Molecular Therapeutics IncExchange CommissionMolecular TherapeuticsChief Executive OfficerTherapeutic Vector EvolutionChief Strategy OfficerPrimary FocusesFocus Area ApproachNobel Prize WinningMolecular Therapeutic Forward Looking StatementsPrivate Securities Litigation Reform ActMolecular TherapeuticLicense AgreementMolecular Therapeutic Vector EvolutionVector EvolutionAnnual ReportQuarterly Report
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - Vimarsana News

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

Published: July 11, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: David...

Source: prnewswire.com
Related Topics:
Adam PearsonDavid KirnNaoki OkamuraD Molecular Therapeutics IncPrnewswire Astellas Pharma IncAstellas Pharma IncMolecular TherapeuticsChief Executive OfficerTherapeutic Vector EvolutionChief Strategy OfficerPrimary FocusesFocus Area ApproachNobel Prize Winning
4DMT Presents Positive Interim Data from Aerosolized 4D-710 - Vimarsana News

4DMT Presents Positive Interim Data from Aerosolized 4D-710

Published: June 7, 2023

Reported data from cohort 1 (n=3, 1E15 vg dose) of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up ...

Source: globenewswire.com
Related Topics:
United StatesKatherine SmithDavid KirnJulian PeiJenniferl Taylor CousarCystic Fibrosis Foundation Therapeutics Development CenterAdult Cystic Fibrosis ProgramExchange CommissionCf FoundationNational Jewish HealthCorporate CommunicationsEuropean Cystic Fibrosis SocietyCystic FibrosisNorth American Cystic Fibrosis ConferenceMolecular TherapeuticsAnnual MeetingChief Executive OfficerExploration CohortSafety DataClinical ActivityEnglj MedBiomarker SummaryExpected MilestonesClinical Data WebcastCystic Fibrosis Lung
Stock Market | FinancialContent Business Page - Vimarsana News

Stock Market | FinancialContent Business Page

Published: June 7, 2023

FinancialContent fully hosted finance channel

Source: financialcontent.com
Related Topics:
United StatesDavid KirnKatherine SmithJulian PeiJenniferl Taylor CousarExchange CommissionCystic Fibrosis Foundation Therapeutics Development CenterAdult Cystic Fibrosis ProgramCf FoundationCorporate CommunicationsEuropean Cystic Fibrosis SocietyNational Jewish HealthCystic FibrosisNorth American Cystic Fibrosis ConferenceMolecular TherapeuticsAnnual MeetingChief Executive OfficerExploration CohortSafety DataClinical ActivityEnglj MedBiomarker SummaryExpected MilestonesClinical Data WebcastCystic Fibrosis Lung
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting - Vimarsana News

4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting

Published: June 7, 2023

Reported data from cohort 1 of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up Quality of life outcomes measured by Cystic... | June 9, 2023

Source: marketscreener.com
Related Topics:
United StatesKatherine SmithJulian PeiJenniferl Taylor CousarDavid KirnCf FoundationNational Jewish HealthAdult Cystic Fibrosis ProgramCystic Fibrosis Foundation Therapeutics Development CenterCorporate CommunicationsEuropean Cystic Fibrosis SocietyExchange CommissionCystic FibrosisNorth American Cystic Fibrosis ConferenceMolecular TherapeuticsAnnual MeetingChief Executive OfficerExploration CohortSafety DataClinical ActivityEnglj MedExpected MilestonesClinical Data WebcastCystic Fibrosis LungTherapeutic Vector Evolution